Harnessing regenerative signals to support tissue repair, cellular communication, and healthier reproductive function.
30–150 nm
typical size of an exosome — thousands of times smaller than a cell
No approved products
the US FDA has stated it has not approved any exosome products
“New drug” in India
cell and stem-cell-derived products need CDSCO approval under the NDCT Rules, 2019
Exosomes are tiny, membrane-wrapped packets released by almost every cell in the body. They belong to a wider family called extracellular vesicles (EVs). Each packet carries a cargo of proteins, fats and genetic messengers such as microRNAs, and cells use them to send signals to one another.
The scientific interest is that exosomes from certain cells — might pass on signals that calm inflammation or support tissue repair, without transplanting the cells themselves. This is the idea behind “exosome therapy.”
An idea being interesting is not the same as a treatment being proven. A 2026 review in the Journal of Extracellular Vesicles notes that, despite the promise, translation of EV-based therapies toward routine clinical use and commercial readiness remains limited.
Scientists are studying exosomes in many fields. The table shows the idea being tested and, importantly, how far the evidence has come:
| Area | The Idea Being Tested | Stage of Evidence |
|---|---|---|
| Reproductive medicine (ovary, womb lining, testis) | Signals that might support follicles, the endometrium or sperm-forming cells | Mainly laboratory and animal studies; very few human trials |
| Skin and hair | Support for wound healing, ageing skin and hair follicles | Early small studies; many cosmetic products are unregulated |
| Joints and bones | Reduction of inflammation and cartilage damage | Mostly preclinical |
| Lung, brain and heart disease | Anti-inflammatory and repair signals | Early-phase trials; no proven treatment yet |
| Diagnostics (blood-based tests) | Using exosomes as markers for disease | Active research; more advanced than treatment uses |
Exosomes are not one standard product. Important open questions include:
In 2019, the US FDA issued a public safety notification after patients suffered serious adverse events following treatment with unapproved products marketed as containing exosomes. It said exosomes used to treat disease are regulated as drugs or biological products and that clinics offering them outside the review process were putting patients at risk.
In the United States, the FDA states that exosome products used to treat diseases are drugs or biological products that need pre-market approval, and that it has approved none.
In India, the New Drugs and Clinical Trials Rules, 2019 treat cell and stem-cell-derived products as “new drugs,” which require approval from the Central Drugs Standard Control Organisation (CDSCO) before clinical use or sale.
The rules continue to evolve, so it is always fair to ask any clinic to show you the approval that covers what it is offering.
These terms are often mixed up. They are different things with different levels of evidence:
| Feature | PRP | Exosomes | |
|---|---|---|---|
| What it is | Platelet concentrate from your own blood | Tiny messenger packets released by cells | |
| Usual source | Your own blood | Cultured cells (often donor-derived), or body fluids | |
| Standardisation | Variable preparation methods | Very variable; no accepted clinical standard | |
| Regulatory position in India | Autologous blood product; used in selected clinical settings | Cell-derived product; approval needed as a new drug | |
| Strength of evidence | Varies by use; some uses studied in randomised trials | Early; mostly laboratory and animal data |
Not as a standard treatment. The US FDA has stated it has approved no exosome products, and in India cell-derived products are regulated as new drugs requiring CDSCO approval. Always ask any clinic to show the approval or trial that covers its product.
There is no proof that they can. Research in the ovary, womb lining and testis is mostly at the laboratory and animal stage. Established fertility care, such as evaluation, medication, IUI and IVF, remains the recommended path.
Not necessarily. Many cosmetic products use the word “exosome” loosely, and their contents are often unverified. Products applied to the skin are not the same as injections, and neither is proven to deliver the benefits claimed.
Safety depends on what is in the product, and that is exactly the problem with unapproved ones. Serious adverse events have been reported after unapproved exosome products in the US. This is why only approved, carefully supervised research should be considered.
Ask for the regulatory approval, the CTRI trial number and ethics committee approval, the product source and its laboratory testing. If a clinic cannot or will not provide these, do not proceed.
Because patients are increasingly approached with exosome offers, and trustworthy information is hard to find. We believe informed patients make safer decisions, whether or not they choose to be treated with us.
Get a proper diagnosis and discuss the proven options for your condition. If you are interested in regenerative approaches, ask your doctor about registered clinical trials, where treatment is supervised and monitored.
Speak with the StemRx team for a proper evaluation and a straightforward discussion of what is proven, what is promising and what to avoid.
